drugset / Trial / NCT06050668
Essential Amino Acid Supplementation for Femoral Fragility Fractures
Phase 2
Recruiting
60 enrolled
Michael C Willey
MEND · collabSlocum Research & Education Foundation · collab
RandomizedParallel-groupDouble-blindSupportive care
Summary
This trial will evaluate the impact of 4 weeks of postoperative essential amino acid (EAA)-based supplementation on muscle morphology after femoral fragility fracture. This trial will assess the ability of EAA-based to increase skeletal muscle metabolic activity, reduce inflammation, and induce muscle fiber hypertrophy, as well as preserve skeletal muscle mass and physical performance up to 6 months after injury. Participants will be randomized in a 1:1 ratio to 1) standard of care (no dietary intervention) or 2) EAA-based supplementation.
Timeline
- Start
- 2024-06-17
- Primary completion
- 2026-07
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MEND™ Repair and Recover® | Unknown | 26.7 g | Oral |